Clinical Hematology International

ISSN (Online):
2590-0048
ISSN (Print):
N/A
Editor(s)-in-Chief:

Mohamad Mohty, Arnon Nagler, Bipin Savani

Clinical Hematology International is the official journal of the International Academy for Clinical Hematology (IACH). Publishing services are provided by Atlantis Press on behalf of IACH which owns the copyright to the journal. Peer review is under the responsibility of IACH.

The journal publishes articles in the broad field of clinical hematology, reporting on novel findings in clinical and translational research and covering topics such as benign & malignant hematology, hematopoietic cell transplantation and cellular therapy. Read full Aims & Scope

Clinical Hematology International is an open access journal, i.e. all articles are immediately and permanently free to read, download, copy & distribute. The journal is published under the CC BY-NC 4.0 user license which defines the permitted 3rd-party reuse of its articles. Publication in this journal is free of charge for Authors. All open access publication fees are subsidized by the International Academy for Clinical Hematology (IACH). Note that this is a promotional offer which applies to all papers submitted before 1 July 2020.

For any questions about this publication, please contact our publishing team.

Journal Metrics

Impact Factor
N/A
CiteScore
N/A
FWCI
N/A
SNIP
N/A
Total Downloads
9,312
Avg. Publication Speed
N/A
SJR
N/A
Total Citations
0
Acceptance Rate
N/A

Repeat Endoscopy Affects Patient Management in Gastrointestinal Graft-Versus-Host Disease: Single-Center Retrospective Analysis

Ehsan Shabbir, Umar Farooq, Burhan Yanes, Margarida Magalhaes-Silverman
In Press, Uncorrected Proof, Available Online: 27 February 2020

Current Status and Future Directions in Graft-Versus-Host Disease Prevention Following Allogeneic Blood and Marrow Transplantation in Adults

Cosmin Tegla, Jun Choi, Maher Abdul-Hay, Frank Cirrone, Kelli Cole, A Samer Al-Homsi
Volume 2, Issue 1, March 2020, Pages 5-12

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Kristian T. Andersen, Maja Hinge, Agoston Gyula Szabo, Erik Segel, Tina Ormstrup, Paw C. Holdgaard, Niels Pallisgaard, Gitte Kerndrup, Torben Plesner
Volume 2, Issue 1, March 2020, Pages 35-39

View More Latest Articles